Your Trusted European Partner for CE Marking and MDR/IVDR Compliance
For Chinese MedTech companies with NMPA experience entering Europe
For Chinese Medical Device and IVD manufacturers with NMPA approval or regulatory experience, entering Europe requires more than familiarity with local regulations. MDR and IVDR demand strong clinical justification, high-quality technical documentation, and ongoing compliance, while Notified Bodies apply heightened scrutiny.
QbD Group helps Chinese companies translate NMPA-based strategies into MDR- and IVDR-compliant European submissions. From EU feasibility and clinical strategy to CE marking and post-market obligations, we provide local expertise to navigate EU market launch with clarity, credibility, and predictability.
Why Europe is challenging for Chinese MedTech companies
Entering Europe presents specific challenges for Chinese manufacturers. Notified Bodies scrutinize clinical evidence, documentation, and post-market readiness. Data from Chinese regulatory frameworks may require EU-specific justification or studies, while language, local representation, and decentralized approval processes add complexity.
QbD Group acts as a European regulatory lead and execution partner, helping you elevate documentation to EU quality standards, design EU-relevant clinical evidence strategies, manage proactive Notified Body interactions, and coordinate mandatory EU roles.
Key challenges we address
Regulatory Differences
NMPA logic differs from EU MDR/IVDR, requiring tailored regulatory strategies for successful market entry.
Clinical Evidence Requirements
MDR and IVDR demand more extensive clinical data than domestic requirements, including EU-specific studies or justifications.
ISO/IEC Compliance
Products must meet EU-recognized standards such as ISO 13485 and related technical and quality requirements.
Notified Body Access
Limited availability and heightened scrutiny from Notified Bodies can delay submissions without proactive planning.
Mandatory EU Roles
Authorized Representative and PRRC obligations must be clearly assigned and maintained for compliance.
Fragmented Execution
Coordinating regulatory, clinical, quality, and post-market activities across Europe is complex and requires integration.
Our structured approach
Regulatory & Technical Documentation
MDR/IVDR classification, CE-marking strategy, technical file creation, GSPR, risk management, usability, and EUDAMED registration.
Clinical Strategy & Operations
CEP/CER development, PMCF planning & execution, real-world evidence, clinical trial execution (CRO role), and medical writing.
Quality Management Systems
ISO 13485 setup & optimization to MDR requirements, audit readiness, supplier quality management, and digital QMS via SciLife.
Software, AI & Digital Health
SaMD & AI-based device guidance, AI Act strategy, cybersecurity requirements, and software lifecycle documentation.
Authorized Representation & Market Entry
EU-REP, UKRP, CH-REP, importer & distributor guidance, and PRRC.
Flexible QA/RA Outsourcing
Interim regulatory roles, QA/RA specialists, and clinical & documentation support.
What you gain
Single European partner
One point of contact for all regulatory, clinical, quality, and post-market needs across Europe.
NMPA-to-MDR expertise
Deep experience translating Chinese regulatory strategies into EU-compliant approaches.
Clarity and credibility
Local expertise to navigate EU market launch with predictability and confidence.
Why QbD Group
Your trusted European regulatory lead for translating NMPA experience into credible, MDR/IVDR-compliant market entry.
NMPA-to-MDR bridge expertise
practical experience adapting Chinese regulatory strategies, clinical data, and documentation to meet EU expectations
Documentation quality elevation
we help raise technical files and clinical evidence to European standards, addressing Notified Body scrutiny head-on
Local European presence
on-the-ground knowledge of EU authority interactions, language requirements, and decentralized approval processes
End-to-end coordination
regulatory, clinical, quality, post-market, and authorized representation managed as one integrated program
Proven track record with Chinese manufacturers
deep understanding of the specific challenges and gaps Chinese MedTech companies face in Europe
FAQ
Frequently asked questions
Talk to a EU MedTech Expert
Complete the form, and our team will help you translate NMPA experience into MDR/IVDR-compliant submissions, design EU-specific clinical strategies, and guide your product through CE marking and post-market obligations.